• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Reactivity-based chemical-genetic study of protein kinases.基于反应性的蛋白激酶化学遗传学研究。
RSC Med Chem. 2022 Mar 30;13(7):783-797. doi: 10.1039/d1md00389e. eCollection 2022 Jul 20.
2
A historical overview of protein kinases and their targeted small molecule inhibitors.蛋白激酶及其靶向小分子抑制剂的历史概述。
Pharmacol Res. 2015 Oct;100:1-23. doi: 10.1016/j.phrs.2015.07.010. Epub 2015 Jul 21.
3
Chemical genetic strategy for targeting protein kinases based on covalent complementarity.基于共价互补性的靶向蛋白激酶的化学遗传策略。
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15046-52. doi: 10.1073/pnas.1111239108. Epub 2011 Aug 18.
4
Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.在蛋白激酶中 FDA 批准的小分子蛋白激酶药物的分子识别。
Molecules. 2022 Oct 21;27(20):7124. doi: 10.3390/molecules27207124.
5
A Chemical-Genetic Approach to Generate Selective Covalent Inhibitors of Protein Kinases.一种生成蛋白激酶选择性共价抑制剂的化学遗传学方法。
ACS Chem Biol. 2017 Jun 16;12(6):1499-1503. doi: 10.1021/acschembio.6b01083. Epub 2017 May 8.
6
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.新型强效 GSK-3β 抑制剂 AF3581 的稳定情绪作用。
Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26.
7
A chemical genetic approach for covalent inhibition of analogue-sensitive aurora kinase.一种化学遗传学方法用于共价抑制类似物敏感的极光激酶。
ACS Chem Biol. 2012 Apr 20;7(4):723-31. doi: 10.1021/cb200465c. Epub 2012 Feb 1.
8
Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.三种丝裂原活化蛋白激酶(MAPK)信号通路成像分析方法的开发与应用,用于为激酶抑制剂提供MAPK模块选择性分析:MK2-EGFP转位、c-Jun和ERK激活。
Methods Enzymol. 2006;414:389-418. doi: 10.1016/S0076-6879(06)14022-7.
9
Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?靶向非催化功能:激酶药物发现的新模式?
J Med Chem. 2022 Feb 10;65(3):1735-1748. doi: 10.1021/acs.jmedchem.1c01978. Epub 2022 Jan 9.
10
Developing irreversible inhibitors of the protein kinase cysteinome.开发蛋白激酶半胱氨酸组的不可逆抑制剂。
Chem Biol. 2013 Feb 21;20(2):146-59. doi: 10.1016/j.chembiol.2012.12.006.

本文引用的文献

1
Direct Target Site Identification of a Sulfonyl-Triazole Covalent Kinase Probe by LC-MS Chemical Proteomics.通过 LC-MS 化学蛋白质组学直接鉴定磺酰三唑共价激酶探针的靶位
Anal Chem. 2021 Sep 7;93(35):11946-11955. doi: 10.1021/acs.analchem.1c01591. Epub 2021 Aug 25.
2
A subcellular map of the human kinome.人类激酶组的亚细胞图谱。
Elife. 2021 May 14;10:e64943. doi: 10.7554/eLife.64943.
3
Generation of a chemical genetic model for JAK3.生成 JAK3 的化学遗传学模型。
Sci Rep. 2021 May 12;11(1):10093. doi: 10.1038/s41598-021-89356-4.
4
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.FDA 批准的小分子蛋白激酶抑制剂的特性:2021 年更新。
Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26.
5
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.奈拉替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌:NALA Ⅲ期临床试验。
J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17.
6
Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis.化学遗传学策略分析激酶靶标结合情况揭示了 FES 在中性粒细胞吞噬作用中的作用。
Nat Commun. 2020 Jun 25;11(1):3216. doi: 10.1038/s41467-020-17027-5.
7
Importance of Quantifying Drug-Target Engagement in Cells.量化细胞中药物-靶点相互作用的重要性。
ACS Med Chem Lett. 2020 Mar 6;11(4):403-406. doi: 10.1021/acsmedchemlett.9b00570. eCollection 2020 Apr 9.
8
Advances in covalent kinase inhibitors.共价激酶抑制剂的研究进展。
Chem Soc Rev. 2020 May 7;49(9):2617-2687. doi: 10.1039/c9cs00720b. Epub 2020 Mar 30.
9
Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.共价与非共价酶抑制:我们应该走哪条路?从分子建模角度看优缺点。
Protein J. 2020 Apr;39(2):97-105. doi: 10.1007/s10930-020-09884-2.
10
Characterising covalent warhead reactivity.描述共价弹头的反应活性。
Bioorg Med Chem. 2019 May 15;27(10):2066-2074. doi: 10.1016/j.bmc.2019.04.002. Epub 2019 Apr 3.

基于反应性的蛋白激酶化学遗传学研究。

Reactivity-based chemical-genetic study of protein kinases.

作者信息

Rezende Miranda Renata, Zhang Chao

机构信息

Department of Chemistry, Loker Hydrocarbon Research Institute, University of Southern California Los Angeles California 90089 USA

Thomas H. Gosnell School of Life Sciences, Rochester Institute of Technology Rochester New York 14623 USA.

出版信息

RSC Med Chem. 2022 Mar 30;13(7):783-797. doi: 10.1039/d1md00389e. eCollection 2022 Jul 20.

DOI:10.1039/d1md00389e
PMID:35923719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9298188/
Abstract

The human protein kinase superfamily comprises over 500 members that operate in nearly every signal transduction pathway and regulate essential cellular processes. Deciphering the functional roles of protein kinases with small-molecule inhibitors is essential to enhance our understanding of cell signaling and to facilitate the development of new therapies. However, it is rather challenging to identify selective kinase inhibitors because of the conserved nature of the ATP binding site. A number of chemical-genetic approaches have been developed during the past two decades to enable selective chemical perturbation of the activity of individual kinases. Herein, we review the development and application of chemical-genetic strategies that feature the use of covalent inhibitors targeting cysteine residues to dissect the cellular functions of protein kinases.

摘要

人类蛋白激酶超家族由500多个成员组成,它们几乎参与了每条信号转导途径,并调节细胞的基本过程。利用小分子抑制剂来阐明蛋白激酶的功能作用,对于增进我们对细胞信号传导的理解以及推动新疗法的开发至关重要。然而,由于ATP结合位点的保守性,鉴定选择性激酶抑制剂颇具挑战性。在过去二十年中,人们开发了许多化学遗传学方法,以实现对单个激酶活性的选择性化学干扰。在此,我们综述了化学遗传学策略的发展与应用,这些策略的特点是使用靶向半胱氨酸残基的共价抑制剂来剖析蛋白激酶的细胞功能。